Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
Liselotte Sabroe | Afp | Getty Images Novo Nordisk, Europe’s largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner … Read more